Multimer monitoring of CMV-specific T cells in research and in clinical applications

Diagnostic Microbiology and Infectious Disease

Volumn 78, Issue 3, 2014, Pages 201-212

  Borchers, Sylvia ^a,b,c   Ogonek, Justyna ^a   Varanasi, Pavankumar R ^a,b,c   Tischer, Sabine ^a   Bremm, Melanie ^d   Eiz Vesper, Britta ^a,b   Koehl, Ulrike ^a,b   Weissinger, Eva M ^a,b,c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Integrated Research and Treatment Center Transplantation   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

Cytomegalovirus; Histamer; Infectious complications; Multimer; Pentamer; Stem cell transplantation; Streptamer; T cell; Tetramer

Indexed keywords

CYTOMEGALOVIRUS; HISTAMER; INFECTIOUS COMPLICATIONS; MULTIMER; PENTAMER; STEM CELL TRANSPLANTATION; STREPTAMER; T CELL; TETRAMER;

ADOPTIVE TRANSFER; CYTOMEGALOVIRUS; EPITOPES, T-LYMPHOCYTE; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEIN MULTIMERIZATION; STAINING AND LABELING;

EID: 84893745696     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.11.007     Document Type: Review

References (90)

1. Akiyama Y., Kuzushima K., Tsurumi T., Yamaguchi K. Analysis of HLA-A24-restricted CMVpp65 peptide-specific CTL with HLA-A*2402-CMVpp65 tetramer. Immunol Lett 2004, 95(2):199-205.
2. Alanio C., Lemaitre F., Law H.K., Hasan M., Albert M.L. Enumeration of human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies. Blood 2010, 115(18):3718-3725.
3. Alanio C., Bouvier I., Jusforgues-Saklani H., Albert M.L. Tracking antigen-specific CD8(+) T cells using MHC class I multimers. Methods Mol Biol 2013, 960:309-326.
4. Altman J.D., Moss P.A., Goulder P.J., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996, 274(5284):94-96.
5. Aubert G., Hassan-Walker A.F., Madrigal J.A., Emery V.C., Morte C., Grace S., et al. Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J Infect Dis 2001, 184(8):955-963.
6. Batard P., Peterson D.A., Devevre E., Guillaume P., Cerottini J.C., Rimoldi D., et al. Dextramers: new generation of fluorescent MHC class I/peptide multimers for visualization of antigen-specific CD8+ T cells. J Immunol Methods 2006, 310(1-2):136-148.
7. Bendelac A., Lantz O., Quimby M.E., Yewdell J.W., Bennink J.R., Brutkiewicz R.R. CD1 recognition by mouse NK1+ T lymphocytes. Science 1995, 268(5212):863-865.
8. Benlagha K., Weiss A., Beavis A., Teyton L., Bendelac A. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J Exp Med 2000, 191(11):1895-1903.
9. Bercovici N., Duffour M.T., Agrawal S., Salcedo M., Abastado J.P. New methods for assessing T-cell responses. Clin Diagn Lab Immunol 2000, 7(6):859-864.
10. Biron K.K. Antiviral drugs for cytomegalovirus diseases. Antiviral Res 2006, 71(2-3):154-163.
11. Boeckh M., Nichols W.G., Papanicolaou G., Rubin R., Wingard J.R., Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 2003, 9(9):543-558.
12. Borchers S., Luther S., Lips U., Hahn N., Kontsendorn J., Stadler M., et al. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2011, 13(3):222-236.
13. Borchers S., Bremm M., Lehrnbecher T., Dammann E., Pabst B., Wolk B., et al. Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation. PLoS One 2012, 7(12):e50248.
14. Borchers S., Weissinger E.M., Pabst B., Ganzenmueller T., Dammann E., Luther S., et al. Expansion of recipient-derived antiviral T cells may influence donor chimerism after allogeneic stem cell transplantation. Transpl Infect Dis 2013, 15:627-633.
15. Britten C.M., Gouttefangeas C., Welters M.J., Pawelec G., Koch S., Ottensmeier C., et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother 2008, 57(3):289-302.
16. Britten C.M., Janetzki S., Ben-Porat L., Clay T.M., Kalos M., Maecker H., et al. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother 2009, 58(10):1701-1713.
17. Brooimans R.A., Boyce C.S., Popma J., Broyles D.A., Gratama J.W., Southwick P.C., et al. Analytical performance of a standardized single-platform MHC tetramer assay for the identification and enumeration of CMV-specific CD8+ T lymphocytes. Cytometry A 2008, 73(11):992-1000.
18. Bunde T., Kirchner A., Hoffmeister B., Habedank D., Hetzer R., Cherepnev G., et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005, 201(7):1031-1036.
19. Bunse C.E., Borchers S., Varanasi P.R., Tischer S., Figueiredo C., et al. Impaired Functionality of Antiviral T Cells in G-CSF Mobilized Stem Cell Donors: Implications for the Selection of CTL Donor. PLoS ONE 2013, 8(12):e77925.
20. Campanelli R., Palermo B., Garbelli S., Mantovani S., Lucchi P., Necker A., et al. Human CD8 co-receptor is strictly involved in MHC-peptide tetramer-TCR binding and T cell activation. Int Immunol 2002, 14(1):39-44.
21. Casalegno-Garduno R., Schmitt A., Yao J., Wang X., Xu X., Freund M., et al. Multimer technologies for detection and adoptive transfer of antigen-specific T cells. Cancer Immunol Immunother 2010, 59(2):195-202.
22. Chalandon Y., Degermann S., Villard J., Arlettaz L., Kaiser L., Vischer S., et al. Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications. Blood 2006, 107(1):389-396.
23. Chen F.E., Aubert G., Travers P., Dodi I.A., Madrigal J.A. HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy. Cytotherapy 2002, 4(1):41-48.
24. Cobbold M., Khan N., Pourgheysari B., Tauro S., McDonald D., Osman H., et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005, 202(3):379-386.
25. Crawford F., Kozono H., White J., Marrack P., Kappler J. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity 1998, 8(6):675-682.
26. Cwynarski K., Ainsworth J., Cobbold M., Wagner S., Mahendra P., Apperley J., et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001, 97(5):1232-1240.
27. Dal Porto J., Johansen T.E., Catipovic B., Parfiit D.J., Tuveson D., Gether U., et al. A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc Natl Acad Sci U S A 1993, 90(14):6671-6675.
28. Daniels M.A., Jameson S.C. Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers. J Exp Med 2000, 191(2):335-346.
29. Davis M.M., Altman J.D., Newell E.W. Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis. Nat Rev Immunol 2011, 11(8):551-558.
30. Einsele H., Roosnek E., Rufer N., Sinzger C., Riegler S., Loffler J., et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002, 99(11):3916-3922.
31. Einsele H., Kapp M., Grigoleit G.U. CMV-specific T cell therapy. Blood Cells Mol Dis 2008, 40(1):71-75.
32. Engstrand M., Tournay C., Peyrat M.A., Eriksson B.M., Wadstrom J., Wirgart B.Z., et al. Characterization of CMVpp65-specific CD8+ T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants. Transplantation 2000, 69(11):2243-2250.
33. Engstrand M., Lidehall A.K., Totterman T.H., Herrman B., Eriksson B.M., Korsgren O. Cellular responses to cytomegalovirus in immunosuppressed patients: circulating CD8+ T cells recognizing CMVpp65 are present but display functional impairment. Clin Exp Immunol 2003, 132(1):96-104.
34. Falta M.T., Fontenot A.P., Rosloniec E.F., Crawford F., Roark C.L., Bill J., et al. Class II major histocompatibility complex-peptide tetramer staining in relation to functional avidity and T cell receptor diversity in the mouse CD4(+) T cell response to a rheumatoid arthritis-associated antigen. Arthritis Rheum 2005, 52(6):1885-1896.
35. Gapin L., Godfrey D.I., Rossjohn J. Natural Killer T cell obsession with self-antigens. Curr Opin Immunol 2013, 25(2):168-173.
36. Gerdemann U., Keirnan J.M., Katari U.L., Yanagisawa R., Christin A.S., Huye L.E., et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther 2012, 20(8):1622-1632.
37. Giest S., Grace S., Senegaglia A.C., Pasquini R., Gonzalo-Daganzo R.M., Fernandez M.N., et al. Cytomegalovirus-specific CD8(+) T cells targeting different HLA/peptide combinations correlate with protection but at different threshold frequencies. Br J Haematol 2010, 148(2):311-322.
38. Gratama J.W., van Esser J.W., Lamers C.H., Tournay C., Lowenberg B., Bolhuis R.L., et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001, 98(5):1358-1364.
39. Gratama J.W., Brooimans R.A., van der Holt B., Sintnicolaas K., van Doornum G., Niesters H.G., et al. Monitoring cytomegalovirus IE-1 and pp 65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations. Cytometry B Clin Cytom 2008, 74(4):211-220.
40. Gratama J.W., Boeckh M., Nakamura R., Cornelissen J.J., Brooimans R.A., Zaia J.A., et al. Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood 2010, 116(10):1655-1662.
41. Haque T., Wilkie G.M., Taylor C., Amlot P.L., Murad P., Iley A., et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002, 360(9331):436-442.
42. Heijnen I.A., Barnett D., Arroz M.J., Barry S.M., Bonneville M., Brando B., et al. Enumeration of antigen-specific CD8+ T lymphocytes by single-platform, HLA tetramer-based flow cytometry: a European multicenter evaluation. Cytometry B Clin Cytom 2004, 62(1):1-13.
43. Hobeika A.C., Morse M.A., Osada T., Ghanayem M., Niedzwiecki D., Barrier R., et al. Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. J Immunother 2005, 28(1):63-72.
44. Holman P.O., Walsh E.R., Jameson S.C. Characterizing the impact of CD8 antibodies on class I MHC multimer binding. J Immunol 2005, 174(7):3986-3991.
45. Horton H., Thomas E.P., Stucky J.A., Frank I., Moodie Z., Huang Y., et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 2007, 323(1):39-54.
46. Janetzki S., Britten C.M., Kalos M., Levitsky H.I., Maecker H.T., Melief C.J., et al. "MIATA"-minimal information about T cell assays. Immunity 2009, 31(4):527-528.
47. Jung T., Schauer U., Heusser C., Neumann C., Rieger C. Detection of intracellular cytokines by flow cytometry. J Immunol Methods 1993, 159(1-2):197-207.
48. Keenan R.D., Ainsworth J., Khan N., Bruton R., Cobbold M., Assenmacher M., et al. Purification of cytomegalovirus-specific CD8 T cells from peripheral blood using HLA-peptide tetramers. Br J Haematol 2001, 115(2):428-434.
49. Klausner R.D., Donaldson J.G., Lippincott-Schwartz J. Brefeldin A: insights into the control of membrane traffic and organelle structure. J Cell Biol 1992, 116(5):1071-1080.
50. Knabel M., Franz T.J., Schiemann M., Wulf A., Villmow B., Schmidt B., et al. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med 2002, 8(6):631-637.
51. Koehl U., Dirkwinkel E., Koenig M., Erben S., Soerensen J., Bader P., et al. Reconstitution of cytomegalovirus specific T cells after pediatric allogeneic stem cell transplantation: results from a pilot study using a multi-allele CMV tetramer group. Klin Padiatr 2008, 220(6):348-352.
52. Komatsu H., Sierro S., VC A., Klenerman P. Population analysis of antiviral T cell responses using MHC class I-peptide tetramers. Clin Exp Immunol. 2003, 134(1):9-12.
53. Lacey S.F., Villacres M.C., La Rosa C., Wang Z., Longmate J., Martinez J., et al. Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp 65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol 2003, 64(4):440-452.
54. Lacey S.F., Diamond D.J., Zaia J.A. Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol Blood Marrow Transplant 2004, 10(7):433-447.
55. Lebowitz M.S., O'Herrin S.M., Hamad A.R., Fahmy T., Marguet D., Barnes N.C., et al. Soluble, high-affinity dimers of T-cell receptors and class II major histocompatibility complexes: biochemical probes for analysis and modulation of immune responses. Cell Immunol 1999, 192(2):175-184.
56. Lee P.P., Yee C., Savage P.A., Fong L., Brockstedt D., Weber J.S., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999, 5(6):677-685.
57. Lehmann P.V., Zhang W. Unique strengths of ELISPOT for T cell diagnostics. Methods Mol Biol 2012, 792:3-23.
58. Lilleri D., Gerna G., Fornara C., Lozza L., Maccario R., Locatelli F. Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood 2006, 108(4):1406-1412.
59. Lilleri D., Fornara C., Chiesa A., Caldera D., Alessandrino E.P., Gerna G. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica 2008, 93(2):248-256.
60. Lilleri D., Gerna G., Zelini P., Chiesa A., Rognoni V., Mastronuzzi A., et al. Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation. PLoS One 2012, 7(7):e41648.
61. Lugthart G., Albon S.J., Ricciardelli I., Kester M.G., Meij P., Lankester A.C., et al. Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy. J Immunother 2012, 35(1):42-53.
62. Luo X.H., Huang X.J., Liu K.Y., Xu L.P., Liu D.H. Protective immunity transferred by infusion of CMV-specific CD8+ T cells within donor grafts: its associations with CMV reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation CMV-specific CD8+ T cells within donor grafts. Biol Blood Marrow Transplant 2010, 16(7):994-1004.
63. Massilamany C., Upadhyaya B., Gangaplara A., Kuszynski C., Reddy J. Detection of autoreactive CD4 T cells using major histocompatibility complex class II dextramers. BMC Immunol 2011, 12:40.
64. Matsuda J.L., Naidenko O.V., Gapin L., Nakayama T., Taniguchi M., Wang C.R., et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 2000, 192(5):741-754.
65. Meyer A.L., Trollmo C., Crawford F., Marrack P., Steere A.C., Huber B.T., et al. Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers. Proc Natl Acad Sci U S A 2000, 97(21):11433-11438.
66. Micklethwaite K., Hansen A., Foster A., Snape E., Antonenas V., Sartor M., et al. Ex vivo expansion and prophylactic infusion of CMV-pp 65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13(6):707-714.
67. Morita Y., Hosokawa M., Ebisawa M., Sugita T., Miura O., Takaue Y., et al. Evaluation of cytomegalovirus-specific cytotoxic T-lymphocytes in patients with the HLA-A*02 or HLA-A*24 phenotype undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2005, 36(9):803-811.
68. Novak E.J., Liu A.W., Nepom G.T., Kwok W.W. MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J Clin Invest 1999, 104(12):R63-R67.
69. Ozdemir E., St John L.S., Gillespie G., Rowland-Jones S., Champlin R.E., Molldrem J.J., et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood 2002, 100(10):3690-3697.
70. Poli C., Raffin C., Dojcinovic D., Luescher I., Ayyoub M., Valmori D. MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer. Haematologica 2013, 98(2):316-322.
71. Ramirez N., Olavarria E. Viral-specific adoptive immunotherapy after allo-SCT: the role of multimer-based selection strategies. Bone Marrow Transplant 2013, 48(10):1265-1270.
72. Rauser G., Einsele H., Sinzger C., Wernet D., Kuntz G., Assenmacher M., et al. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 2004, 103(9):3565-3572.
73. Ravkov E.V., Pavlov I.Y., Hanson K.E., Delgado J.C. Validation of cytomegalovirus immune competence assays for the characterization of CD8(+) T cell responses posttransplant. Clin Dev Immunol 2012, 2012:451059.
74. Riddell S.R., Greenberg P.D. T cell therapy of human CMV and EBV infection in immunocompromised hosts. Rev Med Virol 1997, 7(3):181-192.
75. Romero P., Dunbar P.R., Valmori D., Pittet M., Ogg G.S., Rimoldi D., et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998, 188(9):1641-1650.
76. Samuel E.R., Newton K., Mackinnon S., Lowdell M.W. Successful isolation and expansion of CMV-reactive T cells from G-CSF mobilized donors that retain a strong cytotoxic effector function. Br J Haematol 2013, 160(1):87-100.
77. Sander B., Andersson J., Andersson U. Assessment of cytokines by immunofluorescence and the paraformaldehyde-saponin procedure. Immunol Rev 1991, 119:65-93.
78. Schmitt A., Tonn T., Busch D.H., Grigoleit G.U., Einsele H., Odendahl M., et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011, 51(3):591-599.
79. Schneck JP, Slansky JE, O'Herrin SM, Greten TF. Monitoring antigen-specific T cells using 841 MHC-Ig dimers. Current Protocols in Immunology 35:17.2.1-17.2.17.
80. Scholler J., Singh M., Bergmeier L., Brunstedt K., Wang Y., Whittall T., et al. A recombinant human HLA-class I antigen linked to dextran elicits innate and adaptive immune responses. J Immunol Methods 2010, 360(1-2):1-9.
81. Sili U., Leen A.M., Vera J.F., Gee A.P., Huls H., Heslop H.E., et al. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. Cytotherapy 2012, 14(1):7-11.
82. Sukdolak C., Tischer S., Dieks D., Figueiredo C., Goudeva L., Heuft H.G., et al. CMV-, EBV- and ADV-specific t cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome. Biol Blood Marrow Transplant 2013, 19(10):1480-1492.
83. Sylwester A.W., Mitchell B.L., Edgar J.B., Taormina C., Pelte C., Ruchti F., et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005, 202(5):673-685.
84. Tischer S., Kaireit T., Figueiredo C., Hiller O., Maecker-Kolhoff B., Geyeregger R., et al. Establishment of the reversible peptide-major histocompatibility complex (pMHC) class I Histamer technology: tool for visualization and selection of functionally active antigen-specific CD8(+) T lymphocytes. Int Immunol 2012, 24(9):561-572.
85. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995, 333(16):1038-1044.
86. Wooldridge L., Hutchinson S.L., Choi E.M., Lissina A., Jones E., Mirza F., et al. Anti-CD8 antibodies can inhibit or enhance peptide-MHC class I (pMHCI) multimer binding: this is paralleled by their effects on CTL activation and occurs in the absence of an interaction between pMHCI and CD8 on the cell surface. J Immunol 2003, 171(12):6650-6660.
87. Yang J., James E.A., Huston L., Danke N.A., Liu A.W., Kwok W.W. Multiplex mapping of CD4 T cell epitopes using class II tetramers. Clin Immunol 2006, 120(1):21-32.
88. Yao J., Bechter C., Wiesneth M., Harter G., Gotz M., Germeroth L., et al. Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study. Clin Infect Dis 2008, 46(10):e96-e105.
89. Yee C., Savage P.A., Lee P.P., Davis M.M., Greenberg P.D. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 1999, 162(4):2227-2234.
90. Zhou W., Longmate J., Lacey S.F., Palmer J.M., Gallez-Hawkins G., Thao L., et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood 2009, 113(25):6465-6476.